

Table S1: Classification of healthcare-workers' cohort

	Total	Inpatient unit	Outpatient unit	Both units
Gender				
Female	89	19	68	2
Male	18	11	4	3
Age				
Median	41	41	41	39
Range	(20-73)	(24-73)	(20-64)	(31-60)
Professions				
Physicians	10	4	3	3
Nurses	53	25	28	
Secretaries	14	1	13	
Research coordinators	21		21	
Social workers	4		4	
Medical Assistants	1		1	
Directors	4		2	2

Table S2: Characteristics of CyTOF cancer patients' samples

Patient	Gender	Age	Type of Cancer	Stage	Treatment	SARS-CoV-2 Ab +/-
1	Female	65	Breast	Local	Paclitaxel	Positive
2	Female	69	Breast	Local	Paclitaxel	Negative
3	Male	69	Urinary	Metastatic	Pembrolizumab	Positive
4	Female	48	Lung	Metastatic	Pembrolizumab	Negative

Description of disease status and treatment of the cancer patients SARS-CoV-2 IgG negative and positive samples who were analysed by CyTOF.

Table S3: The antibody panel used for CyTOF

#	Metal	Ab1	Cat#	Clone	Supplier	Supp. cat
1	112Cd	CD45 BCF	029	HI30	Biologend	304002
2	113In	CD44 BCF	007	IM7	Biologend	103014
3	115In	CD8a	517	RPA-T8	Biologend	301053
4	116Cd	CD19	799	HIB19	Biologend	302247
5	141Pr	CD57	775	HNK-1	Biologend	359602
6	142Nd	CD11c	776	3.9	Biologend	301602
7	143Nd	CD117	583	104D2	Fluidigm	3143001B
8	144Nd	CD34	759	581	Biologend	343531
9	145Nd	CD4	778	RPA-T4	Biologend	300541
10	146Nd	CCR5	7	CTC5	R&D Systems	MAB1802

#	Metal	Ab1	Cat#	Clone	Supplier	Supp. cat
11	147Sm	CD20	699	2H7	Biolegend	302343
12	148Nd	CD62L	742	DREG-56	Biolegend	304835
13	149Sm	CD7	535	CD7-6B7	Biolegend	343102
14	150Nd	IgD	791	IA6-2	Biolegend	348235
15	151Eu	CD209	68	DCS-8C1	Biolegend	343002
16	152Sm	CD27	162	O323	Biolegend	302802
17	153Eu	CD45RA	585	HI100	Fluidigm	3153001B
18	154Sm	CD69	63	FN50	Biolegend	310902
19	155Gd	CD25	72	BC96	Biolegend	302602
20	156Gd	CD10	428	HI10a	Fluidigm	3156001B
21	157Gd	PDL-1	358	29E.2A3	Biolegend	329719
22	158Gd	CD123	751	6H6	Biolegend	306027
23	159Tb	CD33	783	WM53	Biolegend	303419
24	160Gd	CD14	719	M5E2	Biolegend	301843
25	161Dy	CXCR5	815	J252D4	Biolegend	356902
26	162Dy	CD11b	159	ICRF44	Biolegend	301312
27	163Dy	CD127	566	A019D5	Biolegend	351302
28	164Dy	CD15	435	W6D3	Fluidigm	3164001B
29	165Ho	CD45RO BCF	015	UCHL1	Biolegend	304202
30	166Er	CD16	86	3G8	Biolegend	302014
31	167Er	CD38	765	HIT2	Biolegend	303535
32	168Er	CCR6 (weak)	725	G034E3	Biolegend	353427
33	169Tm	CCR7 (?)	90	G043H7	Biolegend	353202
34	170Er	CCR4	93	2G12	Biolegend	131202
35	171Yb	CD66b	689	G10F5	Biolegend	305102
36	173Yb	CD3	762	UCHT1	Biolegend	300443
37	174Yb	HLA-DR	581	L243	Fluidigm	3174001B
38	175Lu	PD-1	801	H12.2H7	Fluidigm	3175008B
39	176Yb	CD56	582	CMSSB	Fluidigm	3176003B

A list of the full panel of metal-conjugated antibodies used for CyTOF. Antibodies were in a carrier-free format. Conjugation was performed using the MAXPAR Conjugation Kit.

Table S4: The definition of immune cells based on surface markers

Cell Type	Surface markers*
T helper cells	CD4+
Cytotoxic T cells	CD8+
NK cells	HLA-DR- CD14- CD56+ CD123-
Dendritic cells	HLA-DR+ CD14-
B cells	CD19+ CD20+
Myeloid cells	HLA-DR+ CD11b+ CD33+
Monocytic myeloid cells	HLA-DR- CD11b+ CD14+
Granulocytic myeloid cells	HLA-DR- CD11b+ CD14- CD15+

*The definition of cells includes the pan-hematopoietic marker CD45.